{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/immunizations-travel/management/meningococcal-meningitis/","result":{"pageContext":{"chapter":{"id":"8cb4ca86-fe31-5603-a75e-84413c2b5346","slug":"meningococcal-meningitis","fullItemName":"Scenario: Meningococcal meningitis","depth":2,"htmlHeader":"<!-- begin field 3fd8e2c1-45e3-4ffd-ab42-61087f6fd689 --><h2>Scenario: Meningococcal meningitis</h2><!-- end field 3fd8e2c1-45e3-4ffd-ab42-61087f6fd689 -->","summary":"Covers advice for people travelling to areas endemic with meningococcal group A strain, as well as people travelling to the Hajj or Umra.","htmlStringContent":"<!-- begin item a026f0c2-561d-4978-b3e7-815ba5127697 --><!-- begin field 7bccc973-bd99-47d3-811a-acd900ab5244 --><p>From age 2 months onwards.</p><!-- end field 7bccc973-bd99-47d3-811a-acd900ab5244 --><!-- end item a026f0c2-561d-4978-b3e7-815ba5127697 -->","topic":{"id":"8f89ca7f-a4f5-5e7d-80c8-de5db64ca7f0","topicId":"16d61716-d647-48bc-827b-b2b115ecd0fb","topicName":"Immunizations - travel","slug":"immunizations-travel","lastRevised":"Last revised in January 2021","chapters":[{"id":"25b90177-7e96-59db-b325-abc5f51c8721","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bc7c22b0-dd64-50ad-8110-1fff4c8d6736","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"50f55046-7ca2-567f-94df-9c58f13770a5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2221cdd9-5576-5b5b-ad29-eff077930653","slug":"changes","fullItemName":"Changes"},{"id":"c755b06c-072d-5e60-be73-155dd664c37d","slug":"update","fullItemName":"Update"}]},{"id":"f5871d9a-dff3-59ce-a611-88d2ec41f5ce","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"513a86a0-e305-5e59-bd0d-1fb74a6e8689","slug":"goals","fullItemName":"Goals"},{"id":"87ea4699-bd41-5aeb-aa62-eac1fb591c4d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c8b054a0-ee87-5f9e-aa8f-c1fdf8442a29","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a8eb4582-f05d-5af5-ae78-497260724f93","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6f29b0b8-4b10-5e26-9ece-4cec050b1eb0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"79cb1d1a-ebd1-58c6-9bc5-2bfd006c22c1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8d3187f5-2a99-5108-a7c9-dd601d729381","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"055aad08-f5af-5b2f-bda0-a35213a2a071","slug":"travel-vaccinations","fullItemName":"Travel vaccinations"},{"id":"c8d1352b-616b-5dff-9517-ea235b83e9d9","slug":"diseases-commonly-requiring-vaccination","fullItemName":"Diseases commonly requiring vaccination"},{"id":"041fa115-033d-5525-91ce-c43dbf593bd4","slug":"other-diseases-requiring-vaccination","fullItemName":"Other diseases requiring vaccination"},{"id":"1fe14ee1-a79f-565a-9380-ae3be597d7d5","slug":"where-these-diseases-are-prevalent","fullItemName":"Where these diseases are prevalent"},{"id":"68e09f74-2282-532f-ae34-064998823fc1","slug":"payment-for-travel-vaccinations","fullItemName":"Payment for travel vaccinations"}]},{"id":"0e45089d-2317-5ec5-8c73-f0709c003c48","fullItemName":"Management","slug":"management","subChapters":[{"id":"9c16c0cb-4e78-523d-914f-e884aea62565","slug":"initial-assessment-advice","fullItemName":"Scenario: Initial assessment and advice"},{"id":"f911dc04-ffd0-5a41-a3cb-b724797a7589","slug":"cholera","fullItemName":"Scenario: Cholera"},{"id":"422ff6d3-5810-5d3c-93b3-c5a67faaa0e1","slug":"hepatitis-a","fullItemName":"Scenario: Hepatitis A"},{"id":"01d49a70-70f4-547a-a551-ab524f99c944","slug":"hepatitis-b","fullItemName":"Scenario: Hepatitis B"},{"id":"5c77503c-2f59-5696-908b-125fe0e8e41c","slug":"japanese-encephalitis","fullItemName":"Scenario: Japanese encephalitis"},{"id":"8cb4ca86-fe31-5603-a75e-84413c2b5346","slug":"meningococcal-meningitis","fullItemName":"Scenario: Meningococcal meningitis"},{"id":"0e84be27-375b-55f5-9f51-d0e4cc422b58","slug":"poliomyelitis","fullItemName":"Scenario: Poliomyelitis"},{"id":"37a96f8b-4158-5e62-8e3d-6cedae506976","slug":"rabies","fullItemName":"Scenario: Rabies"},{"id":"8c237a0e-a760-55b2-b7b0-5383b7653be3","slug":"tetanus","fullItemName":"Scenario: Tetanus"},{"id":"85c90e1f-26f4-503b-b0b0-7c5a38930086","slug":"tick-borne-encephalitis","fullItemName":"Scenario: Tick-borne encephalitis"},{"id":"4e817d26-15f3-5ff7-a672-11caa36ffb68","slug":"typhoid-fever","fullItemName":"Scenario: Typhoid fever"},{"id":"5ec20606-2af2-556b-98a6-d8673a21a09d","slug":"yellow-fever","fullItemName":"Scenario: Yellow fever"},{"id":"e0a021ac-7c76-551a-97af-25341142d54f","slug":"hajj-umrah-pilgrims","fullItemName":"Scenario: Hajj and Umrah pilgrims"},{"id":"087d9fbb-1ec6-5f08-8e76-5df3a4a0b863","slug":"rapid-vaccination-courses-vaccination-at-short-notice","fullItemName":"Scenario: Rapid vaccination courses and vaccination at short notice"}]},{"id":"79dee816-dbdb-5426-8db3-2f095eedbff3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f1e9d43f-6815-516a-8511-3fd34a06525d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a69fb594-d4b4-56e6-b46a-6283ead93e30","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"52eea726-d50b-5e4f-a22c-764c1961119d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b2033c1b-25a2-5a58-b99e-00baf9b02a96","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6df4842b-8812-534e-975d-52d29f3a8ee4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"81e42472-4b49-5390-8179-0d131f547700","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"86482706-09b2-5113-bd4e-261c392f6483","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0e45089d-2317-5ec5-8c73-f0709c003c48","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"04d13999-6a63-5011-a8b6-b891c3f3d92c","slug":"indications-for-vaccine","fullItemName":"Indications for vaccine","depth":3,"htmlHeader":"<!-- begin field 29745d93-5f0a-4cc8-ae45-3c2c24d1721c --><h3>Indications for vaccine</h3><!-- end field 29745d93-5f0a-4cc8-ae45-3c2c24d1721c -->","summary":null,"htmlStringContent":"<!-- begin item 5f27235b-9258-4682-9356-13fbc2e20952 --><!-- begin field 26556c60-1789-4d26-b066-4a76eff118f3 --><ul><li><strong>Vaccination with a quadrivalent meningococcal vaccine that protects against the A, C, W, and Y capsular types is recommended for the following groups of people travelling to areas with a high risk of meningococcal meningitis (especially the sub-Saharan 'African Meningitis Belt')</strong><strong>:</strong><ul><li>People staying for extended time periods, such as 1 month or more.</li><li>People visiting savannah regions between the months of December and June (the dry season) when rates of the disease are highest.</li><li>People engaging in activities, such as living or travelling 'rough' (including backpackers), or people living or working with local people, and/or in rural communities.</li><li>Healthcare workers.</li><li>People with asplenia or splenic dysfunction.</li></ul></li><li><strong>Vaccination is also required for all people attending the Hajj (Mecca) and Umra pilgrimages in Saudi Arabia.</strong><ul><li>Proof of vaccination against the A, C, W, and Y capsular groups (covered in the quadrivalent vaccines) is now an entry requirement for pilgrims and seasonal workers travelling to Saudi Arabia.</li></ul></li><li><strong>Outbreaks of meningococcal disease also occur periodically in other parts of the world. </strong>Healthcare providers should check the <a href=\"http://travelhealthpro.org.uk/\" data-hyperlink-id=\"62676543-6d52-44db-b047-a931009ef017\">TravelHealthPro</a> website for up-to-date information.</li><li>Meningococcal C conjugate vaccine is routinely given as part of the childhood immunization programme (see <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-childhood/\">Immunizations - childhood</a> for more information). This vaccine protects against group C disease only. Travellers should be immunized with a quadrivalent vaccine, even if they have previously received the meningococcal C conjugate vaccine.</li></ul><!-- end field 26556c60-1789-4d26-b066-4a76eff118f3 --><!-- end item 5f27235b-9258-4682-9356-13fbc2e20952 -->","subChapters":[{"id":"3f0a160b-a45a-57fd-bf70-562125cfa02d","slug":"basis-for-recommendation-3be","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b836508c-6467-4456-9dbf-cf3ada25390d --><h4>Basis for recommendation</h4><!-- end field b836508c-6467-4456-9dbf-cf3ada25390d -->","summary":null,"htmlStringContent":"<!-- begin item 3be094b1-d6c2-4532-8928-b54a6df91b35 --><!-- begin field 7110badd-b3f5-4ebc-b731-f3ed6d87d232 --><p>The recommendations on indications for meningococcal vaccination are based on expert opinion in the Department of Health publication <em>Immunisation against infectious disease (The Green Book) Chapter 22: Meningococcal disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2016</a>].</p><!-- end field 7110badd-b3f5-4ebc-b731-f3ed6d87d232 --><!-- end item 3be094b1-d6c2-4532-8928-b54a6df91b35 -->","subChapters":[]}]},{"id":"71ea7e91-d742-5cff-b821-3fdf81d92ecf","slug":"available-vaccines-vaccination-schedules","fullItemName":"Available vaccines and vaccination schedules","depth":3,"htmlHeader":"<!-- begin field af0ee811-1da5-4968-bebc-ede908b9eab4 --><h3>Available vaccines and vaccination schedules</h3><!-- end field af0ee811-1da5-4968-bebc-ede908b9eab4 -->","summary":null,"htmlStringContent":"<!-- begin item 61c587c5-4dd5-4460-aca3-7c164195d24d --><!-- begin field d4b06e1f-af62-43c6-959b-0ef79e023102 --><ul><li><strong>A quadrivalent, inactivated, meningitis vaccine is recommended for travellers. A single dose provides cover against strains A, C, Y, and W135 of the disease. Two types are available:</strong><ul><li>Menveo<sup>® </sup>(conjugate vaccine) — use is off-label in children under 2 years of age. </li><li>Nimenrix<sup>® </sup>(conjugate vaccine) — use is off-label in children under 6 weeks of age.</li></ul></li><li><strong>Menveo<sup>®</sup></strong><ul><li>Primary immunization:<ul><li>For adults and children aged 1 year and older, give a single dose of vaccine.</li><li>For children under 1 year of age, give two doses of vaccine, 1 month apart (irrespective of MenC immunization history).</li></ul></li></ul></li><li><strong>Nimenrix<sup>®</sup></strong><ul><li>Primary immunization:<ul><li>For adults and children aged 6 months and older, give a single dose of vaccine.</li><li>For children under 6 months of age, the manufacturer recommends giving two doses of vaccine 2 months apart. Public Health England states that the two doses of vaccine can also be given 1 month apart.</li></ul></li></ul></li></ul><!-- end field d4b06e1f-af62-43c6-959b-0ef79e023102 --><!-- end item 61c587c5-4dd5-4460-aca3-7c164195d24d -->","subChapters":[{"id":"153c1764-ae43-59c6-a9d0-88eb7f057038","slug":"basis-for-recommendation-bc8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a96520bc-9b6e-49f6-8af7-9536cd9992e8 --><h4>Basis for recommendation</h4><!-- end field a96520bc-9b6e-49f6-8af7-9536cd9992e8 -->","summary":null,"htmlStringContent":"<!-- begin item bc89bdd3-b5f5-47a5-84ef-d5656653ddcb --><!-- begin field 6d1b3e7f-a6b3-4ce1-a1fc-80b0446c2361 --><p>The information on available types of quadrivalent meningococcal vaccines and vaccination schedules is based on expert opinion in the Department of Health publication <em>Immunisation against infectious disease (The Green Book) Chapter 22: Meningococcal disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2016</a>] and also on information from the manufacturers of Menveo<sup>®</sup> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">ABPI, 2020b</a>] and Nimenrix<sup>®</sup> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">ABPI, 2020c</a>].</p><h5>Vaccination schedules in infants</h5><ul><li>The information on the primary vaccination schedule for infants under 1 year of age for Menveo<sup>®</sup> is based on expert opinion in <em>The Green Book Chapter 22: Meningococcal vaccines</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2016</a>] and is also consistent with information in the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">BNF, 2021</a>]. Use in this age group is off-license and the manufacturer of Menveo<sup>®</sup> does not provide specific recommendations for a vaccine schedule for children under 2 years old [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">ABPI, 2020b</a>].</li><li>The information on the vaccination schedule for infants under 6 months of age for Nimenrix<sup>®</sup> is based on the manufacturer's recommendations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">ABPI, 2020c</a>] and on expert opinion in <em>The Green Book Chapter 22: Meningococcal vaccines</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2016</a>]. Nimenrix<sup>®</sup> is licensed for use in babies from 6 weeks of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">ABPI, 2020c</a>].</li></ul><!-- end field 6d1b3e7f-a6b3-4ce1-a1fc-80b0446c2361 --><!-- end item bc89bdd3-b5f5-47a5-84ef-d5656653ddcb -->","subChapters":[]}]},{"id":"aba100f2-ab3c-56d1-b981-40414f7c7e60","slug":"contraindications-to-vaccine","fullItemName":"Contraindications to vaccine","depth":3,"htmlHeader":"<!-- begin field 303b3517-136e-40c0-b303-5e5b77d64475 --><h3>Contraindications to vaccine</h3><!-- end field 303b3517-136e-40c0-b303-5e5b77d64475 -->","summary":null,"htmlStringContent":"<!-- begin item 88717e7a-6dc7-4d6d-a7d1-de836cf79709 --><!-- begin field c78fe63c-a3c0-4f7c-91d6-3b1dd1b5a1ce --><ul><li><strong>Do not give quadrivalent meningococcal vaccine if the person has:</strong><ul><li>Had a confirmed anaphylactic reaction to a previous dose of the vaccine.</li><li>Had a confirmed anaphylactic reaction to any component of the vaccine.</li></ul></li><li><strong>Postpone quadrivalent meningococcal vaccination if the person has a current severe febrile illness.</strong><ul><li>Minor illness without fever or systemic upset is <em>not</em> a valid reason to postpone immunization.</li></ul></li><li><strong>Meningococcal vaccines may be given to pregnant women when clinically indicated.</strong> There is no evidence of risk from vaccinating pregnant women or those who are breastfeeding with inactivated virus, bacterial vaccines, or toxoids.</li></ul><!-- end field c78fe63c-a3c0-4f7c-91d6-3b1dd1b5a1ce --><!-- end item 88717e7a-6dc7-4d6d-a7d1-de836cf79709 -->","subChapters":[{"id":"61a30607-9e6b-5449-b0ee-cee52fa99bfd","slug":"basis-for-recommendation-bab","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 36b3a782-fb52-4071-b55d-7a74cef022e3 --><h4>Basis for recommendation</h4><!-- end field 36b3a782-fb52-4071-b55d-7a74cef022e3 -->","summary":null,"htmlStringContent":"<!-- begin item babac0c7-c78a-48c7-a7d5-19076c5d798b --><!-- begin field 448e0c51-f880-44e1-b0c1-9e1ea11c580c --><p>The information on contraindications to quadrivalent meningococcal vaccination is based on expert opinion in the Department of Health publication <em>Immunisation against infectious disease (The Green Book) Chapter 22: Meningococcal disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2016</a>] and <em>Chapter 6: Contraindications and special considerations</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2017a</a>].</p><!-- end field 448e0c51-f880-44e1-b0c1-9e1ea11c580c --><!-- end item babac0c7-c78a-48c7-a7d5-19076c5d798b -->","subChapters":[]}]},{"id":"25c1f9be-983e-501c-ac03-61c9b4f24294","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e4480c35-d2bb-45bf-a0de-11abc68570c5 --><h3>Adverse effects</h3><!-- end field e4480c35-d2bb-45bf-a0de-11abc68570c5 -->","summary":null,"htmlStringContent":"<!-- begin item 2700851f-3982-4fa6-88c4-711e0360b38c --><!-- begin field 3ca85c23-b182-4a9b-8e6e-1abc7f8c7076 --><ul><li><strong>Menveo<sup>®</sup></strong><ul><li>Commonly reported reactions include injection site reactions (such as pain, erythema, induration, and pruritus), headache, nausea, rash, and malaise.</li></ul></li><li><strong>Nimenrix<sup>®</sup></strong><ul><li>Commonly reported reactions include injection site reactions (such as pain, erythema, and swelling), headache, nausea, irritability, drowsiness, and loss of appetite.</li></ul></li></ul><!-- end field 3ca85c23-b182-4a9b-8e6e-1abc7f8c7076 --><!-- end item 2700851f-3982-4fa6-88c4-711e0360b38c -->","subChapters":[{"id":"7d98c2ed-e80d-54e5-bc0e-d31aafb992e4","slug":"basis-for-recommendation-57a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3db10c12-b6f0-4fb7-b996-7484337eab13 --><h4>Basis for recommendation</h4><!-- end field 3db10c12-b6f0-4fb7-b996-7484337eab13 -->","summary":null,"htmlStringContent":"<!-- begin item 57aa3f1e-2484-461a-8c0b-2feba9e58ae7 --><!-- begin field 51e4e367-87c9-4f4c-8cda-0d5150f2147c --><p>The information on adverse effects of quadrivalent meningococcal vaccination is based on expert opinion in the Department of Health publication <em>Immunisation against infectious disease (The Green Book) Chapter 22: Meningococcal disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2016</a>].</p><!-- end field 51e4e367-87c9-4f4c-8cda-0d5150f2147c --><!-- end item 57aa3f1e-2484-461a-8c0b-2feba9e58ae7 -->","subChapters":[]}]},{"id":"f2c09944-c784-5b8a-b14e-2249f85134db","slug":"how-to-administer-meningococcal-vaccine","fullItemName":"How to administer meningococcal vaccine","depth":3,"htmlHeader":"<!-- begin field 509e67f7-06e1-4e9a-a484-e3a088ee97da --><h3>How to administer meningococcal vaccine</h3><!-- end field 509e67f7-06e1-4e9a-a484-e3a088ee97da -->","summary":null,"htmlStringContent":"<!-- begin item 70d68638-1e09-40c3-9212-2d7761796ba7 --><!-- begin field 0ab10d1b-3a41-4bbd-afb1-dfef5547c3a4 --><ul><li><strong>Obtain written or verbal consent at the time of vaccination for people aged over 16 years.</strong><strong> For younger people it is usual to get consent from a person with parental responsibility.</strong><ul><li>Adults over 18 years of age are presumed to be competent to consent to treatment provided they can comprehend and retain the information they are given, and they can consider the facts and make an informed decision.</li></ul></li><li><strong>Ensure that:</strong> <ul><li>There are no <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-travel/management/meningococcal-meningitis/#contraindications-to-vaccine\">contraindications</a> to the vaccine.</li><li>The person, parent, or carer has been fully informed about the vaccine and the vaccination procedure.</li><li>Possible <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-travel/management/meningococcal-meningitis/#adverse-effects\">adverse reactions</a> have been discussed and the person, parent, or carer is aware of how to manage them. </li><li>The vaccine is correct, has been stored appropriately, and has not expired. </li></ul><ul><li>The vaccination site has been washed with soap and water if it is visibly dirty. </li></ul></li><li><strong>Meningococcal vaccine is usually given by intramuscular (IM) injection,</strong> into the upper arm in children and adults, or the anterolateral thigh in infants under 1 year of age. However, if the person has a bleeding disorder, the vaccine should be given by deep subcutaneous (SC) injection to reduce the risk of bleeding. </li><li><strong>Meningococcal vaccine can be given at the same time as other vaccines.</strong> If an additional vaccine is required on the same day, use separate limbs if possible, or inject at sites at least 2.5 cm apart. </li><li><strong>Record the date of administration, vaccine and product name, batch number, expiry date, dose administered, and site of administration for each vaccine.</strong> </li><li><strong>Observe the person after vaccination to detect immediate adverse reactions.</strong> Ensure any bleeding has stopped and check for any symptoms of anaphylaxis before they leave.<ul><li>Anaphylaxis is extremely rare, and usually becomes apparent within minutes. By the time the site has been checked for bleeding and documentation has been completed, most reactions will have become apparent. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li></ul></li></ul><!-- end field 0ab10d1b-3a41-4bbd-afb1-dfef5547c3a4 --><!-- end item 70d68638-1e09-40c3-9212-2d7761796ba7 -->","subChapters":[{"id":"47d362a3-c8a5-55ce-abdd-8743e4e61995","slug":"basis-for-recommendation-068","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1bd36a74-c873-4d4e-b16b-45e97254dd00 --><h4>Basis for recommendation</h4><!-- end field 1bd36a74-c873-4d4e-b16b-45e97254dd00 -->","summary":null,"htmlStringContent":"<!-- begin item 068416fb-6f98-4289-a5cd-1a884c388cba --><!-- begin field f782330f-16ee-4385-bac6-801348a7650d --><p>The recommendations on how to administer meningococcal vaccines are based on expert opinion in the Department of Health Publication <em>Immunisation against infectious disease</em> <em>(The Green Book) Chapter 22: Meningococcal disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2016</a>], <em>Chapter 2: Consent</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013e</a>], <em>Chapter 4: Immunisation procedures</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013f</a>], and <em>Chapter 8: Vaccine safety and adverse effects</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013g</a>], and are also pragmatic, based on what CKS considers to be good clinical practice.</p><h5>Obtaining consent</h5><ul><li>Consent for immunizations does not legally have to be in writing, but must be given voluntarily by a fully informed person who is able to make and communicate their decision. For children not competent to give or withhold consent, a person with parental responsibility can provide this [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013e</a>].</li></ul><h5>Site of administration</h5><div><ul><li>In people over the age of 1 year, vaccines are routinely given into the deltoid muscle as it is convenient, providing easy access, and it reduces the risk of localized reactions, which are common when vaccines are given subcutaneously.</li><li>The gluteal muscle should be avoided. The needle may not penetrate through adipose tissue into the muscle, and this may cause a poor immunological response to the vaccine. In addition, there is a risk of damage to underlying structures such as the sciatic nerve [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013f</a>].</li></ul></div><!-- end field f782330f-16ee-4385-bac6-801348a7650d --><!-- end item 068416fb-6f98-4289-a5cd-1a884c388cba -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}